TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
LACTATING WOMAN:~Inclusion Criteria:~* 18-40 years.~* Pregnancy longer than week 36.~* Single Pregnancy.~* Planned breastfeeding.~* No current thyroid disease.~* Agree not to take iodine supplementation except as provided through the study.~Exclusion Criteria:~* Patient who is not expected to adhere to the research protocol. Plans for pregnancy within 6 months after delivery.~* Vegans.~CONTROL WOMAN:~Inclusion Criteria:~* 18-40 years.~* No current thyroid disease.~* Agree not to iodine supplementation during the study.~Exclusion Criteria:~* Patient who is not expected to adhere to the research protocol.~* Plans for pregnancy within 6 months of study entry.~* Vegans.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- iodine (Type: EXPERIMENTAL): iodine containing multivitamin~150 ug, 1 tablet daily
- placebo (Type: PLACEBO_COMPARATOR): placebo, 1 tablet Daily of a non-iodine containing multivitamin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients electing to undergo primary or revision total hip or knee arthroplasty~* Currently taking an ACE-I~Exclusion Criteria:~* Trauma patients~* Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy patients, chronic steroid use)~* Patients with history of severe hypertension related illness such as hypertension associated with stroke or myocardial infarction~* Patients in who continuation of their ACE-I is expressly mandated by their prescribing physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuation Group (Type: EXPERIMENTAL): Subjects randomized to this group will continue their ACE-I through the day of surgery
- Cessation Group (Type: EXPERIMENTAL): Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose \>48 hours prior to surgery)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ENTegral Artificial Larynx Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age more than or equal to 18 years old~* Is indicated for total laryngectomy (first intention)~* Must be able to comply with study requirements~* Must be able to understand and be willing to provide written informed consent~Exclusion Criteria:~* Any condition that precludes the implantation of the ENTegral AL~* Existing coagulation disorder~* Contraindication for general anesthesia~* Tumoral extension outside of the larynx invading through extra-laryngeal structures~* Previous radiotherapy~* Life-expectancy \< 12 months~* Be pregnant of breastfeeding or intention to becoming pregnant during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ENTegral Artificial Larynx implant (Type: EXPERIMENTAL): ENTegral Artificial Larynx implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old~* diagnosed with inflammatory Bowel Disease (ulcerative colitis and Crohn's disease)~* with mild or moderate anaemia~Exclusion Criteria:~* not diagnosed with bowel obstruction~* not diagnosed with short bowel syndrome~* not taking iron supplement or antioxidant vitamins and minerals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Protective Factors Against Elderly Suicide

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Attempted suicide and / or suicidal ideas~* Informed and agreed to participate~Exclusion Criteria:~* Cognitive disorders~* Refusal to participate

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suicide attempt or ideas (Type: None): Elderly patients who attempted suicide or who emitted suicidal ideas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating females. Females of child bearing potential must have a negative serum pregnancy test prior to randomization, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]).~* Diagnosis of UC confirmed by established criteria, regardless of disease duration.~* Moderate to severely active UC, defined by a modified Mayo Score ≥6, with confirmed endoscopic activity by central reader (Mayo endoscopic subscore ≥2).~* Require initiation with adalimumab for induction of remission.~* Ability of subject to swallow study drug capsules.~* Ability of subject to participate fully in all aspects of this clinical trial.~* Written informed consent must be obtained and documented.~Exclusion Criteria:~* Prior treatment with a TNF antagonist or biological therapy.~* Prior treatment with MTX.~* Disease limited to the rectum (proctitis).~* Documented presence of antibodies against adalimumab.~* Contraindication for anti-TNF or MTX therapy.~* Contraindication for endoscopy.~* Ostomy.~* Planned surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MTX 12.5 (Type: ACTIVE_COMPARATOR): Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
- MTX 25 mg (Type: ACTIVE_COMPARATOR): Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
- Placebo (Type: PLACEBO_COMPARATOR): Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pegvisomant on GH/IGF-I Relationship in GHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age~* Confirmed severe AGHD~* GH response \<9 mU/l (preferably \<4) to insulin-induced hypoglycaemia or glucagon stimulation test plus (These tests will have taken place as part of routine management).~* Full, stable pituitary replacement therapy~* Willing to provide informed consent~Exclusion Criteria:~* Unwilling to provide written consent~* Current GH therapy~* Pharmacological doses of glucocorticoids~* Any acute illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compression Therapy for Acute Lower Limb Cellulitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical features of acute class 2-4 cellulitis of the lower leg~* They have an Ankle Brachial Pressure Index between ≥0.8 and ≤1.3 or Toe Brachial Pressure Index ≥ 0.7 for treatment with full compression therapy~* They have a Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score of less than 6 and no clinical signs of necrotising fasciitis~* They are able to tolerate compression therapy, keeping the bandages in place above the level of visible cellulitis for the treatment period~* 18 years or older capable of giving informed consent~* They are admitted to the study setting~Exclusion Criteria:~* Clinical signs or symptoms of peripheral arterial disease~* Unable to give informed consent~* Unable/unwilling to wear compression bandages for study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Compression therapy (Type: EXPERIMENTAL): compression therapy
- Standard treatment (Type: ACTIVE_COMPARATOR): standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients diagnosed with Hemoglobin SS (HB SS), the most common type of sickle cell disease~* patients diagnosed with Hemoglobin SC (HB SC), the second most common type of sickle cell disease.~* patients diagnosed with Hemoglobin sickle beta-zero thalassemia ( HB SB0thal) or Hemoglobin sickle thalassemia (HB SBthal)~Must meet clinical criteria for ACS- an infiltrate on Chest X-ray and one of the following:~* Respiratory symptoms/signs (patients pulse oximetry \< 92% or oxygen saturation \< 2% below their baseline, tachypnea, cough, and increased work of breathing)~* Fever~* Chest pain AND~Patients' eligible for a simple transfusion based on one of the following criteria:~* Hypoxemia (patients pulse oximetry \< 92% or oxygen saturation \< 2% below their baseline)~* Hemoglobin \< 5 gm/dl~* Increased work of breathing~Exclusion Criteria:~* Patient requires exchange transfusion within first 24 hours of admission~* Patient requires PCCU transfer within first 24 hours of admission~* Hemoglobin \> 9gm/dl secondary to these patients requiring an exchange transfusion

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Bi-level Positive Airway Pressure Device (Type: EXPERIMENTAL): BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
- Sham CPAP (Type: SHAM_COMPARATOR): Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have given written informed consent.~2. Aged 18 years and over.~3. Confirmed histological diagnosis of squamous cell carcinoma of the tongue.~4. primary tumor, regional nodes, metastasis (TNM) stage T1-2 Nx M0.~5. Eligible for local surgery with curative intent.~6. World Health Organization (WHO) Performance status 0-2.~Exclusion Criteria:~1. Previous oncologic surgery and/or external beam radiation therapy on the tongue and oral floor.~2. Major surgery (Oro-facial) within the past 4 weeks or incompletely healed surgical incisions before starting study therapy.~3. Any unresolved toxicity greater than National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE version 4.03) grade 2 from previous anti-cancer therapy.~4. Pregnancy or nursing (women of child-bearing potential).~5. Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression.~6. Previous enrolment in the present study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Holmium-166 microspheres (Type: EXPERIMENTAL): Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ammonia Levels and Cognitive Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* cognitive decline (suspected or documented)~* able to get blood drawn~Exclusion Criteria:~* liver disease/cirrhosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-cirrhotic patients with cognitive impairment (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For Eligibility subjects must have:~* failed one or two previous courses of therapy.~* have no active brain metastasis. Treated non-active brain metastasis are acceptable.~* cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva \[erlotinib\] or Iressa \[gefitinib\]) in the past.~* has demonstrated progressive disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KD019 (Type: EXPERIMENTAL): KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
- Erlotinib (Type: ACTIVE_COMPARATOR): Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read and understand English~* Has a BioFlo implanted port in place less than one (1) year~* Evidence of a patent BioFlo port catheter prior to enrollment in the study~* Is receiving active treatment (i.e., receiving a therapeutic drug) through the BioFlo implanted port~* Current treatment protocol projected to continue for a minimum of three (3) months~* Anticipates receiving care at the identified centers for 12 months following enrollment in the study~* Does not receive care of BioFlo implanted port at any other facility~Exclusion Criteria:~* Has documented heparin platelet antibody (i.e., could not be randomized to either group) or other allergy to heparin~* Receiving therapeutic dose of an anticoagulant (e.g.,warfarin, heparin, enoxaparin)~* Does not meet one or more of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
- Intervention Group (Type: EXPERIMENTAL): Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Agent-Enhanced Document Explanation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. understand spoken and written English (assessed by verbally asking candidates if they understand spoken and written English)~2. Must be an established patient in the Boston Medical Center clinics.~Exclusion Criteria:~* An issue determined by the patient's physician that would make this study inappropriate.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Human RA (Type: NO_INTERVENTION): A sham research informed consent form will be explained by a research assistant
- ECA (Type: EXPERIMENTAL): A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
- ECA + Human RA (Type: EXPERIMENTAL): A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mask Adhesive Institutional Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults patients age 18 to 85 (inclusive)~* Adult patients treated with NIV~* Able to read, write, and speak English~* Able to provide written informed consent~* Willing to have facial hair removed for adhesive placement (if required)~Exclusion Criteria:~* Pre-existing allergy to tape or adhesive;~* Blisters, open skin or pre-existing skin condition that may impact the ability to support removal of the mask adhesive without tearing the skin~* pregnant (for females of childbearing age);~* Individuals sentenced to such an institution under a criminal or civil statute,~* Individuals detained in other facilities by virtue of statutes or commitment procedures which provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial, or sentencing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Mask with Mask Adhesive/Arm 1 (Type: ACTIVE_COMPARATOR): Patients will be randomized to AF531 if they receive mask adhesive with mask on the first study night then the mask without mask adhesive(Performatrak) on the second study night.
- Mask without Mask Adhesive/Arm 2 (Type: PLACEBO_COMPARATOR): Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then they will receive the mask with the mask adhesive on the second study night.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues